http://type2diabetestreatment.net/diabetes-type-2/novel-oral-glds-associated-with-lower-cvd-mortality-risk-vs-insulin/
February 10, 2017 Novel Oral GLDs Associated With Lower CVD, Mortality Risk vs Insulin Share this content:
lower mortality with novel oral glucose lowering drugs in type 2 diabetes
HealthDay News – For patients with type 2 diabetes, novel oral glucose lowering drugs are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published online in Diabetes, Obesity and Metabolism.
Thomas Nyström, MD, from Karolinska Institutet in Stockholm, and colleagues compared use of novel oral glucose lowering drugs (either dipeptidyl-peptidase-4 inhibitors [DPP-4i] or sodium glucose cotransporter-2 inhibitors) with insulin treatment in a propensity score matched analysis involving 21,758 patients matched in a 1:1 ratio.
Continue Reading Below
The researchers observed reductions in the risk of all-cause mortality, CVD, and hypoglycemia in the novel glucose lowering drug group vs the insulin group (hazard ratios [HRs], 0.56 [95% CI, 0.49-0.64], 0.85 [95% CI, 0.73-0.99], and 0.26 [95% CI, 0.12-0.57], respectively).
Dapagliflozin correlated with lower risks of all-cause mortality and CVD (HRs, 0.44 [95% CI, 0.28-0.70] and 0.51 [95% CI, 0.30-0.86], respectively), while DPP-4i correlated with reduced risk of all-cause mortality (HR, 0.59 [95% CI, 0.51-0.67]) but not CVD (HR, 0.87 [95% CI, 0.75-1.01]).
"Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality," the authors wrote.
Disclosures
Several authors disclosed financial ties to the pharmaceutical industry.
Related Articles- Arm Circumference May Predict Survival in Older Patients With CVD
- Postprandial Hyperglycemia Associated With CVD in Type 2 Diabetes
Reference
Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients [published online January 24, 2017]. Diabetes Obes Metab. doi: 10.1111/dom.12889
Loading links....Endocrinology Advisor Articles
- Polycystic Ovary Syndrome and Increased Risk for Disordered Eating
- Uncertainty in Medicine: An Endocrinologist"s Perspective
- New Or Rapidly Deteriorating Type 2 Diabetes May Be Indicative of Pancreatic Cancer
- Continuous Glucose Monitoring Improves HbA1c in T1D
- How Low is Too Low?: Safety and Tolerability of Extremely Low LDL Examined
- ADA Releases 2017 Standards of Medical Care in Diabetes
- Harmonized Testosterone Reference Ranges Established for Men
- Culture of Medical Training and Student Well-Being
- AHA Scientific Statement: Effects of Meal Timing on CV Health
- Type 1 Diabetes Associated With Gut Inflammation
- Nutrition and Insulin Management Guidelines for Exercise in Type 1 Diabetes
- Childhood Blood Pressure Trajectory Indicative of Cardiovascular Disease Risk
- Intentional Weight Loss in Postmenopausal Women Associated With Reduced Endometrial Cancer RIsk
- Novel Oral GLDs Associated With Lower CVD, Mortality Risk vs Insulin
- Incident CHD Risk Elevated With High Triglycerides, Low HDL
Sign Up for Free e-Newsletters
Type 2 Diabetes TreatingRenal Diabetic Diet
Advanced Diabetic Solutions
Original Article
#Diabetes_Type_2
#obesity_help
No comments:
Post a Comment